11553 related articles for article (PubMed ID: 12296474)
21. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
22. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
23. Recombinant viral vectors: cancer vaccines.
Harrop R; John J; Carroll MW
Adv Drug Deliv Rev; 2006 Oct; 58(8):931-47. PubMed ID: 17030074
[TBL] [Abstract][Full Text] [Related]
24. Biologic response modifiers: therapeutic approaches to lymphoproliferative diseases.
Stickney DR; Foon KA
Curr Opin Oncol; 1992 Oct; 4(5):847-55. PubMed ID: 1457499
[TBL] [Abstract][Full Text] [Related]
25. The role of biological response modifiers in disease control.
Campos M; Godson D; Hughes H; Babiuk L; Sordillo L
J Dairy Sci; 1993 Aug; 76(8):2407-17. PubMed ID: 8408871
[TBL] [Abstract][Full Text] [Related]
26. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
27. Psoriatic arthritis treatment: biological response modifiers.
Mease PJ; Antoni CE
Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii78-82. PubMed ID: 15708944
[TBL] [Abstract][Full Text] [Related]
28. Immunological monitoring and clinical trials of biological response modifiers.
Urba WJ; Baseler MW
Cancer Chemother Biol Response Modif; 1988; 10():473-91. PubMed ID: 2484322
[No Abstract] [Full Text] [Related]
29. Engineered affinity proteins for tumour-targeting applications.
Friedman M; Ståhl S
Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
[TBL] [Abstract][Full Text] [Related]
30. Biological response modifiers: their possibilities for cancer treatment.
Franz G
Verh K Acad Geneeskd Belg; 1989; 51(2):177-85; discussion 186-7. PubMed ID: 2800688
[TBL] [Abstract][Full Text] [Related]
31. Immunological monitoring and clinical trials of biological response modifiers.
Kopp WC; Holmlund JT; Urba WJ
Cancer Chemother Biol Response Modif; 1994; 15():226-86. PubMed ID: 7540029
[No Abstract] [Full Text] [Related]
32. Prospects for the therapeutic use of anticancer vaccines.
Chamberlain RS
Drugs; 1999 Mar; 57(3):309-25. PubMed ID: 10193685
[TBL] [Abstract][Full Text] [Related]
33. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
34. Biological response modifiers used in cancer biotherapy.
Kuroki M; Miyamoto S; Morisaki T; Yotsumoto F; Shirasu N; Taniguchi Y; Soma G
Anticancer Res; 2012 Jun; 32(6):2229-33. PubMed ID: 22641656
[TBL] [Abstract][Full Text] [Related]
35. Cancer therapy by biological response modifiers.
Herberman RB
Arzneimittelforschung; 1987 Feb; 37(2A):246-50. PubMed ID: 2436633
[TBL] [Abstract][Full Text] [Related]
36. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
37. Immunological monitoring and clinical trials of biological response modifiers.
Baseler MW; Urba WJ
Cancer Chemother Biol Response Modif; 1992; 13():205-29. PubMed ID: 1382527
[No Abstract] [Full Text] [Related]
38. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
39. Potential adverse events with biologic response modifiers.
Kong JS; Teuber SS; Gershwin ME
Autoimmun Rev; 2006 Aug; 5(7):471-85. PubMed ID: 16920574
[TBL] [Abstract][Full Text] [Related]
40. [Interferon in the treatment of solid tumors].
Lukac J; Seso D; Daković N; Ferencić Z; Cajkovac V; Belicza M; Soos E; Ikić D; Kusić Z
Lijec Vjesn; 1994; 116(11-12):303-7. PubMed ID: 7536287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
